Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 References  













TERN-501







Add links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

TERN-501
Legal status
Legal status
  • Investigational
Identifiers

  • N-[3,5-dichloro-4-(1-methyl-6-oxo-5-propan-2-ylpyridazin-3-yl)oxyphenyl]-5-oxo-4H-1,2,4-oxadiazole-3-carboxamide

PubChem CID
ChEMBL
Chemical and physical data
FormulaC17H15Cl2N5O5
Molar mass440.24 g·mol−1
3D model (JSmol)

  • CC(C)C1=CC(=NN(C1=O)C)OC2=C(C=C(C=C2Cl)NC(=O)C3=NOC(=O)N3)Cl

  • InChI=1S/C17H15Cl2N5O5/c1-7(2)9-6-12(22-24(3)16(9)26)28-13-10(18)4-8(5-11(13)19)20-15(25)14-21-17(27)29-23-14/h4-7H,1-3H3,(H,20,25)(H,21,23,27)

  • Key:WFIWVDVCNWOMQV-UHFFFAOYSA-N

TERN-501 is a selective thyromimetic drug that is being developed for the treatment of non-alcoholic fatty liver disease.[1][2]

References

[edit]
  1. ^ Finan, Brian; Parlee, Sebastian D.; Yang, Bin (April 2021). "Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH". Molecular Metabolism. 46: 101153. doi:10.1016/j.molmet.2020.101153. PMC 8085542. PMID 33359400.
  • ^ Karim, Gres; Bansal, Meena B (2023). "Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis". TouchREVIEWS in Endocrinology. 19 (1): 60–70. doi:10.17925/EE.2023.19.1.60. ISSN 2752-5457. PMC 10258622. PMID 37313239.


    • Stub icon

    This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=TERN-501&oldid=1203830961"
    Categories: 
    ●Thyroid hormone receptor beta agonists
     ●Chloroarenes
     ●Oxadiazoles
     ●Pyridazines
     ●Anilides
     ●Isopropyl compounds
     ●Experimental drugs developed for non-alcoholic fatty liver disease
     ●Pharmacology stubs
     Hidden categories: 
    ●Articles with short description
     ●Short description matches Wikidata
     ●Orphaned articles from September 2023
     ●All orphaned articles
     ●Drugs with non-standard legal status
     ●Chemical articles without CAS registry number
     ●Chemical pages without ChemSpiderID
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Articles without UNII source
     ●Drugs missing an ATC code
     ●Articles containing unverified chemical infoboxes
     ●All stub articles
      


    ●This page was last edited on 5 February 2024, at 17:59 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki